JP2017500028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500028A5 JP2017500028A5 JP2016538019A JP2016538019A JP2017500028A5 JP 2017500028 A5 JP2017500028 A5 JP 2017500028A5 JP 2016538019 A JP2016538019 A JP 2016538019A JP 2016538019 A JP2016538019 A JP 2016538019A JP 2017500028 A5 JP2017500028 A5 JP 2017500028A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- region shown
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical group C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 34
- 239000000611 antibody drug conjugate Substances 0.000 claims 33
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 33
- 229940127089 cytotoxic agent Drugs 0.000 claims 26
- 239000002254 cytotoxic agent Substances 0.000 claims 26
- 231100000599 cytotoxic agent Toxicity 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 230000003796 beauty Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 101000864130 Homo sapiens Dipeptidase 3 Proteins 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 102100029857 Dipeptidase 3 Human genes 0.000 claims 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000000562 conjugate Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 2
- 229930195731 calicheamicin Natural products 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 208000012988 ovarian serous adenocarcinoma Diseases 0.000 claims 2
- 201000003709 ovarian serous carcinoma Diseases 0.000 claims 2
- 201000010198 papillary carcinoma Diseases 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 102000053267 human DPEP3 Human genes 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915321P | 2013-12-12 | 2013-12-12 | |
| US61/915,321 | 2013-12-12 | ||
| PCT/US2014/070110 WO2015089449A2 (en) | 2013-12-12 | 2014-12-12 | Novel anti-dpep3 antibodies and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017500028A JP2017500028A (ja) | 2017-01-05 |
| JP2017500028A5 true JP2017500028A5 (enExample) | 2018-04-19 |
Family
ID=53371972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538019A Pending JP2017500028A (ja) | 2013-12-12 | 2014-12-12 | 新規の抗ｄｐｅｐ３抗体および使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10189910B2 (enExample) |
| EP (1) | EP3080607A4 (enExample) |
| JP (1) | JP2017500028A (enExample) |
| KR (1) | KR20160097336A (enExample) |
| CN (2) | CN106104273A (enExample) |
| AU (1) | AU2014361856A1 (enExample) |
| BR (1) | BR112016013048A2 (enExample) |
| CA (1) | CA2932476A1 (enExample) |
| CL (1) | CL2016001432A1 (enExample) |
| IL (1) | IL245946A0 (enExample) |
| MX (1) | MX2016007369A (enExample) |
| PE (1) | PE20160993A1 (enExample) |
| PH (1) | PH12016501109A1 (enExample) |
| SG (1) | SG11201604664PA (enExample) |
| WO (1) | WO2015089449A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106232626B (zh) | 2014-03-27 | 2022-05-03 | 鸟石生物公司 | 结合人大麻素1(cb1)受体的抗体 |
| SG10201908685QA (en) | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| CN107921146A (zh) | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc) |
| HK1252696A1 (zh) | 2015-08-28 | 2019-05-31 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| BR112018006633A2 (en) * | 2015-09-30 | 2018-10-23 | Bird Rock Bio, Inc. | antibodies that bind to human cannabinoid receptor 1 (cb1) |
| CA3027445A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| US11352420B2 (en) | 2016-07-01 | 2022-06-07 | Paracrine Therapeutics Ab | Methods and compositions for PDGF-CC inhibition |
| JP6730525B2 (ja) | 2016-11-21 | 2020-07-29 | ナノストリング テクノロジーズ，インコーポレイティド | 化学組成物とそれを利用する方法 |
| WO2018107109A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Novel anti-kremen2 antibodies and methods of use |
| CA3047522A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
| JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ） |
| WO2018148595A1 (en) * | 2017-02-10 | 2018-08-16 | Washington University | Antibodies to tip1 and methods of use thereof |
| JP7140103B2 (ja) * | 2017-03-10 | 2022-09-21 | コニカミノルタ株式会社 | 治療有効性の予測方法 |
| WO2018213680A1 (en) * | 2017-05-19 | 2018-11-22 | Abbvie Stemcentrx Llc | Diagnostic antibodies and methods of use |
| CR20190550A (es) * | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a pd-1 y métodos de uso |
| JPWO2019167874A1 (ja) * | 2018-02-27 | 2021-03-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ａｐｏａ４に対するモノクローナル抗体、免疫学的測定方法及び測定用キット |
| SG11202011274YA (en) | 2018-05-14 | 2020-12-30 | Nanostring Technologies Inc | Chemical compositions and methods of using same |
| AU2019282778A1 (en) | 2018-06-08 | 2020-12-10 | Alector Llc | Anti-Siglec-7 antibodies and methods of use thereof |
| CN113517029A (zh) * | 2020-08-07 | 2021-10-19 | 广东省计划生育科学技术研究所（广东省计划生育专科医院） | 一种调控dpep3提高精液质量的方法 |
| US12473368B2 (en) | 2020-11-13 | 2025-11-18 | Ibio, Inc. | CD25 antibodies |
| US12129302B2 (en) | 2021-08-25 | 2024-10-29 | Ibio, Inc. | Anti-CD-25 antibody |
| KR20250010670A (ko) * | 2022-05-16 | 2025-01-21 | 시티 오브 호프 | 항-cd84 항체 및 이의 용도 |
| CN116693672B (zh) * | 2023-06-15 | 2025-08-08 | 郑州伊美诺生物技术有限公司 | 抗3型人副流感病毒单克隆抗体及其制备方法和应用 |
| CN119306830B (zh) * | 2023-07-11 | 2025-06-20 | 东莞市朋志生物科技有限公司 | 抗皮质醇抗体、检测皮质醇的试剂和试剂盒 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5191066A (en) | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| AU2559799A (en) | 1998-01-22 | 1999-08-09 | Genentech Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
| ATE320436T1 (de) | 1998-08-27 | 2006-04-15 | Spirogen Ltd | Dimere pyrrolobenzodiazepine |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| EP1578447A4 (en) | 2002-10-31 | 2009-06-03 | Genentech Inc | METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION |
| EP1419786A1 (en) | 2002-11-13 | 2004-05-19 | Bracco Imaging S.p.A. | Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US20050152894A1 (en) | 2003-09-05 | 2005-07-14 | Genentech, Inc. | Antibodies with altered effector functions |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| PT2270010E (pt) | 2004-03-01 | 2012-03-12 | Spirogen Ltd | Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2 |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| ES2533695T3 (es) | 2004-03-02 | 2015-04-14 | Seattle Genetics, Inc. | Anticuerpos cargados parcialmente y métodos para su conjugación |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| WO2006065533A2 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| EP1874816A4 (en) | 2005-04-26 | 2010-08-25 | Medimmune Inc | MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| AR060978A1 (es) | 2006-05-30 | 2008-07-23 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos |
| JP2009539374A (ja) | 2006-06-06 | 2009-11-19 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション | 腫瘍性幹細胞が富化された組成物及びそれを含む方法 |
| AU2007262635B2 (en) * | 2006-06-23 | 2014-09-11 | Adc Therapeutics Sa | Polynucleotides and polypeptide sequences involved in cancer |
| US20080220448A1 (en) | 2006-09-01 | 2008-09-11 | Blincko Stuart J | Antigenic protein conjugates and process for preparing same |
| LT3207941T (lt) | 2006-09-07 | 2020-04-10 | Scott & White Memorial Hospital | Būdai ir kompozicijos difterijos toksino ir interleukino 3 konjugatų pagrindu |
| EP2074226A2 (en) * | 2006-09-19 | 2009-07-01 | Novartis AG | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| US8309354B2 (en) | 2007-01-22 | 2012-11-13 | Macrogenics West, Inc. | Human cancer stem cells |
| CA2683568A1 (en) | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| EP2764874A1 (en) | 2007-07-17 | 2014-08-13 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic stem cells and uses thereof |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| US20100226925A1 (en) | 2007-09-14 | 2010-09-09 | Amgen Inc. | Homogeneous Antibody Populations |
| WO2009039192A2 (en) * | 2007-09-17 | 2009-03-26 | The Regents Of The University Of Californina | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| US20110033378A1 (en) | 2008-01-18 | 2011-02-10 | Medlmmune, Llc. | Cysteine Engineered Antibodies For Site-Specific Conjugation |
| WO2010037134A2 (en) | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| WO2010081171A2 (en) | 2009-01-12 | 2010-07-15 | Cyntellect, Inc. | Laser mediated sectioning and transfer of cell colonies |
| US20120071634A1 (en) | 2009-03-19 | 2012-03-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody Constant Region Variant |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| PH12012501664A1 (en) | 2010-02-21 | 2012-10-22 | Bayer Healthcare Llc | Method for activation and conjugation of biomolecules |
| WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| CN102933236B (zh) * | 2010-04-15 | 2014-10-08 | 斯皮罗根有限公司 | 吡咯并苯二氮卓类及其结合物 |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| AU2011265054B2 (en) | 2010-06-08 | 2016-09-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| CA2809864A1 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| EP2638066A4 (en) | 2010-11-09 | 2015-06-03 | Medimmune Llc | ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION |
| CA2820630A1 (en) | 2010-12-09 | 2012-06-14 | Bayer Healthcare Llc | Dimeric molecular complexes with free cysteine residues and conjugates thereof |
| KR101381319B1 (ko) * | 2011-04-06 | 2014-04-04 | 한국생명공학연구원 | 간세포 분화 탐지용 ｄｎａ 메틸화 마커 및 이를 이용한 탐지 방법 |
| WO2013052108A2 (en) * | 2011-10-03 | 2013-04-11 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of ovarian cancer |
| WO2013055987A1 (en) * | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| CA2859667C (en) | 2011-12-20 | 2022-05-24 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| AR090549A1 (es) * | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| MX2014012889A (es) * | 2012-05-01 | 2014-11-14 | Genentech Inc | Anticuerpos e inmunoconjugados anti-pmel17. |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| JP6273205B2 (ja) | 2012-10-05 | 2018-01-31 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| RS58921B1 (sr) | 2012-10-12 | 2019-08-30 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
| KR102626525B1 (ko) | 2013-02-08 | 2024-01-19 | 노파르티스 아게 | 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위 |
| KR20160018579A (ko) | 2013-06-04 | 2016-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항체를 접합하기 위한 조성물 및 방법 |
| KR20160044042A (ko) | 2013-08-28 | 2016-04-22 | 스템센트알엑스 인코포레이티드 | 부위-특이적 항체 접합 방법 및 조성물 |
| EP4190809A1 (en) | 2014-02-11 | 2023-06-07 | Seagen Inc. | Selective reduction of proteins |
| EP3209334A2 (en) | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
-
2014
- 2014-12-12 CN CN201480073038.XA patent/CN106104273A/zh active Pending
- 2014-12-12 BR BR112016013048A patent/BR112016013048A2/pt not_active Application Discontinuation
- 2014-12-12 SG SG11201604664PA patent/SG11201604664PA/en unknown
- 2014-12-12 PE PE2016000784A patent/PE20160993A1/es unknown
- 2014-12-12 AU AU2014361856A patent/AU2014361856A1/en not_active Abandoned
- 2014-12-12 MX MX2016007369A patent/MX2016007369A/es unknown
- 2014-12-12 JP JP2016538019A patent/JP2017500028A/ja active Pending
- 2014-12-12 EP EP14870395.2A patent/EP3080607A4/en not_active Withdrawn
- 2014-12-12 WO PCT/US2014/070110 patent/WO2015089449A2/en not_active Ceased
- 2014-12-12 KR KR1020167018641A patent/KR20160097336A/ko not_active Withdrawn
- 2014-12-12 CN CN201811271990.7A patent/CN109575136A/zh active Pending
- 2014-12-12 CA CA2932476A patent/CA2932476A1/en not_active Abandoned
-
2016
- 2016-05-31 IL IL245946A patent/IL245946A0/en unknown
- 2016-06-10 PH PH12016501109A patent/PH12016501109A1/en unknown
- 2016-06-10 CL CL2016001432A patent/CL2016001432A1/es unknown
- 2016-06-13 US US15/181,353 patent/US10189910B2/en not_active Expired - Fee Related
- 2016-10-21 US US15/331,282 patent/US9777071B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500028A5 (enExample) | ||
| JP2016538318A5 (enExample) | ||
| JP2016536020A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| JP2020152735A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| JP2017518040A5 (enExample) | ||
| JP2018127469A5 (enExample) | ||
| JP2016531914A5 (enExample) | ||
| JP2015509948A5 (enExample) | ||
| HRP20201399T1 (hr) | Novi modulatori i postupci njihove uporabe | |
| JP2017519759A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| JP2014511179A5 (enExample) | ||
| JP2019516394A5 (enExample) | ||
| HRP20191169T1 (hr) | Konjugati antidll3-protutijelo-pbd i njihove uporabe | |
| JP2018534933A5 (enExample) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2013543498A5 (enExample) | ||
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| JP2016510002A5 (enExample) | ||
| JP2014522850A5 (enExample) |